register

News & Trends - MedTech & Diagnostics

The big themes impacting ASX-listed healthcare companies

Health Industry Hub | January 23, 2023 |

MedTech News: The COVID-19 pandemic has significantly impacted many ASX-listed healthcare companies, such as ResMed, Fisher and Paykel Healthcare, Sonic Healthcare and CSL.

Sonic Healthcare and Australian Clinical Labs have benefitted as COVID-19 testing has surged during the last couple of years.

That said, the past three years hasn’t been an unexpected gain for all. Supply chain challenges have impacted companies like ResMed, while lockdowns have prevented CSL from executing its flagship product.

In 2023, the Australian healthcare sector is facing two headwinds. The short-term headwind is the Chinese reopening. The long-term headwind is the impact inflation has on production, according to Citi’s Australian health analysts.

The top three ASX healthcare companies – CSL, ResMed and Fisher and Paykel Healthcare – have pricing power and resilient demand which should offset the negative impact of inflation and/or a potential recession, at least to some degree, according to the analysts.

CSL is focused on plasma collection, recovery in Vifor sales post-COVID, the Argenx CIDP P3 clinical trial data in Q2 2023, and the transition to the Terumo plasma collection devices.

In the case of ResMed, the company continues to benefit from the Philips CPAP medical device recall for sleep aponea. ResMed believes that it will have the capacity to supply the entire market once the availability of semiconductors improves, potentially reducing the likelihood of a quick return to market by Philips.

On the other hand, Ramsay Health Care and Integral Diagnostics continue to face the uncertainty around COVID-19, workforce challenges and the pace of recovery of their businesses. Cochlear could also be hit if the pace and severity of China’s COVID-19 reopening changes dramatically.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Horizon Scanning Report Reveals Systemic Gap

Horizon scanning report exposes critical systemic gaps demanding immediate reform

Health Industry Hub | November 15, 2024 |

Medicines Australia has released the report from its 2024 Horizon Scanning Forum, a cornerstone of its Strategic Agreement with the […]

More


News & Trends - Pharmaceuticals

Is the NHS decline a warning for Australia's healthcare system?

Is the NHS decline a warning for Australia’s healthcare system?

Health Industry Hub | November 15, 2024 |

A decline in the performance of England’s National Health Service (NHS) offers important insights for Australia and other nations that […]

More


News & Trends - MedTech & Diagnostics

NSW’s first integrated care centre for prostate cancer patients sets new standard

NSW’s first integrated care centre for prostate cancer patients sets new standard

Health Industry Hub | November 15, 2024 |

In a NSW-first, a centre dedicated to the comprehensive treatment of prostate cancer, offering free, integrated care for both public […]

More


News & Trends - MedTech & Diagnostics

Medtronic and Abbott compete for leadership in next-gen leadless pacemakers

Medtronic and Abbott compete for leadership in next-gen leadless pacemakers

Health Industry Hub | November 15, 2024 |

Medtronic is advancing its leadless pacemaker technology with the release of the Micra VR2 and Micra AV2, highlighting new features […]

More


This content is copyright protected. Please subscribe to gain access.